Canadian Generics Group Launches Cost-Saving Campaign
Generic Drugs Save Canadians $33.7bn Annually
The CGPA is drawing attention to the cost savings Canadians can benefit from through the use of generic drugs via a PSA-style digital campaign.
You may also be interested in...
A renewed commitment from Canada’s government to a universal national pharmacare program, included in the latest federal budget, has been welcomed by the country’s generics and biosimilars industry.
A dedicated website will spearhead a public education campaign initiated by Sandoz Canada for biosimilars, as their influence and presence continue to grow in the North American market. Sandoz itself is planning a portfolio of five products by the middle of 2021.
Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.